中期因子mRNA在非小细胞肺癌患者外周血中的表达及其临床意义  

Midkine mRNA expression in peripheral blood of patients with non-small-cell lung cancer and its clinical significance

作　　者：马志红[1] 闵丽姗[1] 沈琦斌[2] 李鸿伟[2] 王斌[3] 戴利成[1] 

机构地区：[1]浙江省湖州市中心医院湖州市分子医学重点实验室,313000 [2]浙江省湖州市中心医院心胸外科,313000 [3]浙江省湖州市中心医院呼吸内科,313000

出　　处：《中华实验外科杂志》2012年第8期1475-1477,共3页Chinese Journal of Experimental Surgery

摘　　要：目的探讨非小细胞肺癌（NSCLC）患者外周血中中期因子（MK）mRNA的表达及其临床意义。方法采用定量聚合酶链反应（PCR）法检测87例NSCLC患者、35例肺良性疾病患者及30例健康志愿者外周血中MKmRNA的表达。结果NSCLC患者外周血中MKmRNA的相对表达（6．749±1．117）与良性疾病患者（7．988±0．633）和健康志愿者（8．156±0．525）比较，差异有统计学意义（P〈0．05），而后两者比较差异无统计学意义（P〉0．05）。NSCLC患者外周血中MKmRNA表达水平与其临床TNM分期，细胞分化程度及淋巴结转移密切相关（P〈0．05），而与年龄、性别、吸烟与否和病理类型无明显相关（P〉0．05）。结论外周血MKmRNA有望成为NSCLC微转移检测的有效标志物。Objective To evaluate the expression of human midkine mRNA in peripheral blood of patients with non-small-cell lung cancer （NSCLC）. Methods The levels of midkine mRNA expression in 78 patients with NSCLC, 35 patients with lung benign lesion and 30 healthy volunteers were evaluated by SYBR Green I real-time reverse transcription polymerase chain reaction （PCR）. Results The relative midkine mRNA expression in patients with NSCLC （ 6. 749 ± 1.117） was significantly lower than in pa- tients with benign pulmonary disease （ 7. 988 ± 0. 633 ） and healthy volunteers （ 8. 156 ± 0. 525 ） （ both P 〈 0. 05） , but there was no significant difference between the latter two groups （P 〉 0. 05 ）. Moreover, higher relative midkine mRNA expression in NSCLC patients was correlated with clinical stages, differentia- tion, and metastasis （P 〈 0. 05 ）, but not with sex, age, smoking habit and pathological types （P 〉 O. 05）. Conclusion These findings support our hypothesis that midkine mRNA is a promising biomarker in peripheral blood of patients with NSCLC.

关 键 词：中期因子 肿瘤标志物 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]